Endocrine Abstracts

Introduction: The Food and Drug Administration (FDA) had issued warnings on the increased risk of diabetic ketoacidosis and Fournier’s gangrene with patients using Sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Herein, we report a case of simultaneous Fournier’s gangrene and diabetic ketoacidosis after initiation of treatment with Empagliflozin.Case Presentation: We report a case of a 54-year-old woman with type 2 diabetes on empagliflozin...